Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Spero Therapeutics Second Quarter 202 Earnings Conference Call.
Spero Therapeutics Inc. (SPRO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,189,235 | $2,782,810 | -8% | 0% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 885,631 | $2,072,377 | +309% | 0% |
| 3. | Anson Investments Amin Nathoo And Moez Kassam | 421,956 | $987,377 | -33% | 0.08% |
| 4. | Citadel Investment Group Ken Griffin | 376,458 | $880,912 | -6% | 0% |
| 5. | Ionic Capital Management Bart Baum | 195,939 | $458,497 | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.24 | 39,727 | $207,970.85 | 5,321,231 | 2022-04-26 | Filing | |
| $8.79 | 16,885 | $148,392.13 | 5,281,504 | 2022-03-30 | Filing | |
| $8.79 | 33,115 | $291,027.87 | 5,264,619 | 2022-03-30 | Filing | |
| $7.63 | 8,006 | $61,053.76 | 5,231,504 | 2022-03-14 | Filing | |
| $7.63 | 15,702 | $119,743.45 | 5,223,498 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.51 | 25,240 | $63,352.40 | 986,851 | 2026-05-04 | Filing | |
| $2.36 | 50,816 | $119,925.76 | 1,012,091 | 2026-02-06 | Filing | |
| $2.36 | 37,101 | $87,558.36 | 1,062,907 | 2026-02-06 | Filing | |
| $2.36 | 18,652 | $44,018.72 | 742,506 | 2026-02-06 | Filing | |
| $2.24 | 3,471 | $7,775.04 | 761,158 | 2026-02-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,636 | $41,186 | 0% | |
| 2. | 8,300 | $18 | 0.01% |
News See All
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week
We recently published a list of Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week.
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
14 Cheap Penny Stocks to Buy According to Analysts
In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript
Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1.
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
In this article, we will take a detailed look at the 15 Cash-Rich Penny Stocks Hedge Funds Are Buying. For a quick overview of such stocks, read our article 5 Cash-Rich Penny Stocks Hedge Funds Are...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript
Ted Jenkins: Thank you, operator, and thank you all for participating in today's conference call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Hedge Fund Resource Center